Immune-Onc Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
2ndary - Private
- Investors
-
22
Immune-Onc Therapeutics General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to develop novel therapies in immunology and oncology by targeting myeloid cells. The company has a focused platform approach and differentiated pipeline and has developed first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment, enabling patients to have access to new immunomodulatory.
Contact Information
Website
www.immune-onc.comCorporate Office
- 795 San Antonio Road
- Palo Alto, CA 94303
- United States
Corporate Office
- 795 San Antonio Road
- Palo Alto, CA 94303
- United States
Immune-Onc Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 9. Later Stage VC (Series B3) | 05-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 20-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series B) | 30-Mar-2021 | Completed | Clinical Trials - General | |||
| 6. Grant | 04-Aug-2020 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 01-Aug-2020 | Completed | Pre-Clinical Trials | |||
| 4. Debt - PPP | 13-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 18-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 28-Jun-2017 | $500K | $7.5M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 01-Sep-2016 | $7M | $7M | Completed | Product Development |
Immune-Onc Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series B | 20,988,105 | $0.000100 | 6% | $1.58 | $1.58 | 1x | $1.58 | 17.37% |
| Series A | 8,634,934 | $0.000100 | 6% | $0.81 | $0.81 | 1x | $0.81 | 7.15% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Immune-Onc Therapeutics Comparisons
Industry
Financing
Details
Immune-Onc Therapeutics Competitors (35)
One of Immune-Onc Therapeutics’s 35 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Biond Biologics | Venture Capital-Backed | Nahariya, Israel | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| NextCure | Formerly VC-backed | Beltsville, MD | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Immune-Onc Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immune-Onc Therapeutics Patents
Immune-Onc Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250179173-A1 | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor | Pending | 17-Feb-2022 | ||
| EP-4426740-A2 | Novel anti-lilrb2 antibodies and derivative products | Inactive | 01-Nov-2021 | ||
| AU-2021365142-A1 | Novel anti-lilrb2 antibodies and derivative products | Pending | 21-Oct-2020 | ||
| AU-2021365142-A9 | Novel anti-lilrb2 antibodies and derivative products | Pending | 21-Oct-2020 | ||
| CA-3198844-A1 | Novel anti-lilrb2 antibodies and derivative products | Pending | 21-Oct-2020 | C07K16/2803 |
Immune-Onc Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immune-Onc Therapeutics Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brightway Future Capital | Venture Capital | Minority | ||
| Proxima Ventures (China) | Venture Capital | Minority | ||
| Triwise Capital | Venture Capital | Minority | ||
| WuXi Biologics | Corporation | Minority | ||
| Leukemia & Lymphoma Society | Not-For-Profit Venture Capital | Minority |
Immune-Onc Therapeutics FAQs
-
When was Immune-Onc Therapeutics founded?
Immune-Onc Therapeutics was founded in 2016.
-
Where is Immune-Onc Therapeutics headquartered?
Immune-Onc Therapeutics is headquartered in Palo Alto, CA.
-
What is the size of Immune-Onc Therapeutics?
Immune-Onc Therapeutics has 18 total employees.
-
What industry is Immune-Onc Therapeutics in?
Immune-Onc Therapeutics’s primary industry is Drug Discovery.
-
Is Immune-Onc Therapeutics a private or public company?
Immune-Onc Therapeutics is a Private company.
-
What is Immune-Onc Therapeutics’s current revenue?
The current revenue for Immune-Onc Therapeutics is .
-
How much funding has Immune-Onc Therapeutics raised over time?
Immune-Onc Therapeutics has raised $138M.
-
Who are Immune-Onc Therapeutics’s investors?
Brightway Future Capital, Proxima Ventures (China), Triwise Capital, WuXi Biologics, and Leukemia & Lymphoma Society are 5 of 22 investors who have invested in Immune-Onc Therapeutics.
-
Who are Immune-Onc Therapeutics’s competitors?
Agenus, Biond Biologics, NGM Biopharmaceuticals, NextCure, and Adaptimmune Therapeutics are some of the 35 competitors of Immune-Onc Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
